Xencor (XNCR) Receiving Somewhat Positive News Coverage, Report Finds
Media coverage about Xencor (NASDAQ:XNCR) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Xencor earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.7927338171285 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
XNCR opened at $41.70 on Wednesday. Xencor has a 1 year low of $18.97 and a 1 year high of $44.88. The company has a market capitalization of $2.28 billion, a P/E ratio of -39.71 and a beta of 1.59.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. Xencor had a negative net margin of 137.35% and a negative return on equity of 20.32%. analysts anticipate that Xencor will post -2.24 EPS for the current fiscal year.
In other Xencor news, insider John J. Kuch sold 25,000 shares of Xencor stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $41.64, for a total transaction of $1,041,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP John R. Desjarlais sold 35,000 shares of Xencor stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $40.36, for a total transaction of $1,412,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 566,651 shares of company stock worth $22,763,811. 4.70% of the stock is currently owned by corporate insiders.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.